The score is driven primarily by solid financial performance (healthy cash generation, prudent leverage, and strong ROE) and supportive valuation (moderate P/E and a strong dividend yield). Technicals remain bullish, but overbought signals (high RSI and Stochastics) temper the rating due to elevated near-term reversal risk.
Positive Factors
Cash generation
Efficient conversion of earnings into cash (OCF/net income 1.15; FCF/net income 1.08) supports durable funding for capex, working capital and dividends. Reliable cash conversion in a staffing model improves resilience through demand cycles and funds reinvestment without heavy external financing.
Prudent leverage and strong ROE
A low debt-to-equity ratio (0.25) with strong ROE (17.17%) and a healthy equity ratio (40.45%) indicates disciplined capital deployment and balance-sheet flexibility. This structural financial strength supports strategic investment, potential M&A, and cushions the business against economic downturns.
Stable margins and steady revenue trend
Consistent revenue trajectory and stable gross/EBITDA margins (gross margin 18.15%) point to operational efficiency in staffing and outsourcing services. Predictable margins and recurring client relationships support long-term cash flow visibility and scalable on-site service delivery.
Negative Factors
Low net profit margin
A structural net margin of 2.37% leaves limited room to absorb cost inflation or pricing pressure and constrains retained earnings for reinvestment. In a labor-intensive staffing business, low net profitability reduces the buffer for adverse cycles and limits strategic flexibility over the medium term.
Volatile free cash flow growth
Despite solid conversion ratios, volatility in free cash flow growth introduces uncertainty in capital allocation and dividend planning. For a company reliant on client demand and project timing, FCF swings can hinder consistent reinvestment and impair ability to fund opportunistic initiatives.
Modest revenue growth rate
Modest top-line expansion (roughly mid-single-digit average and only 1.58% in the latest period) limits the pace at which the company can scale overhead absorption and improve margins. In a low-margin staffing model, slow revenue growth constrains long-term margin expansion and market share gains.
HIRAYAMA HOLDINGS Co.Ltd. (7781) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥13.03B
Dividend Yield3.74%
Average Volume (3M)6.31K
Price to Earnings (P/E)11.3
Beta (1Y)0.68
Revenue Growth2.96%
EPS Growth14.65%
CountryJP
Employees3,096
SectorIndustrials
Sector Strength72
IndustryStaffing & Employment Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding8,156,400
10 Day Avg. Volume9,400
30 Day Avg. Volume6,313
Financial Highlights & Ratios
PEG Ratio0.94
Price to Book (P/B)1.58
Price to Sales (P/S)0.22
P/FCF Ratio8.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HIRAYAMA HOLDINGS Co.Ltd. Business Overview & Revenue Model
Company DescriptionHIRAYAMA HOLDINGS Co.,Ltd. provides in-sourcing and temporary staffing services. Its services include manufacturing outsourcing, manufacturing temporary staffing, and personnel placement services; and engineer placement and entrusted development engineer services, such as dispatching its engineer staff to the engineering section of its clients. It also offers GENBA KAIZEN consulting, and human resources education services. The company was formerly known as HIRAYAMA Co., Ltd. and changed its name to HIRAYAMA HOLDINGS Co.,Ltd. in March 2017. The company was founded in 1955 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyHIRAYAMA HOLDINGS generates revenue through the sale of its medical devices and healthcare solutions. The company has established key revenue streams from the direct sale of its products to healthcare institutions and the provision of maintenance and support services. Additionally, HIRAYAMA may engage in partnerships with other medical technology firms to co-develop products or expand its market reach, further contributing to its earnings. The company also benefits from ongoing demand in the healthcare sector, driven by an aging population and increasing healthcare spending.
Strong overall fundamentals supported by steady revenue growth, stable operating margins, and robust cash conversion (operating cash flow to net income of 1.15). Balance sheet leverage is prudent (debt-to-equity 0.25) with solid ROE (17.17%), though the net profit margin is relatively low (2.37%) and free cash flow growth shows some volatility.
Income Statement
78
Positive
HIRAYAMA HOLDINGS Co.Ltd. exhibits strong revenue growth with a consistent upward trajectory over the years, highlighted by a 1.58% growth in the latest period. The company maintains healthy profit margins, with a gross profit margin of 18.15% and a net profit margin of 2.37% for the most recent year. EBIT and EBITDA margins also show stability, indicating efficient operational management. However, the net profit margin remains relatively low, suggesting room for improvement in cost management or pricing strategies.
Balance Sheet
72
Positive
The balance sheet reflects a solid financial position with a manageable debt-to-equity ratio of 0.25, indicating prudent leverage use. The return on equity is robust at 17.17%, showcasing effective utilization of shareholder funds. The equity ratio of 40.45% suggests a strong capital structure, though there is potential risk if debt levels increase significantly.
Cash Flow
75
Positive
Cash flow analysis reveals a remarkable free cash flow growth, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.15, demonstrating efficient conversion of earnings into cash. The free cash flow to net income ratio of 1.08 further supports the company's ability to generate cash relative to its net income, although fluctuations in free cash flow growth rates suggest potential volatility.
Breakdown
Jun 2024
Jun 2023
Jun 2022
Jun 2021
Jun 2020
Income Statement
Total Revenue
36.22B
35.29B
31.67B
27.98B
23.04B
Gross Profit
6.57B
5.97B
5.23B
4.80B
4.01B
EBITDA
1.39B
1.26B
1.00B
799.51M
768.63M
Net Income
858.16M
757.11M
549.13M
409.36M
413.46M
Balance Sheet
Total Assets
12.36B
12.29B
10.11B
8.71B
8.17B
Cash, Cash Equivalents and Short-Term Investments
6.06B
5.95B
4.33B
3.41B
3.88B
Total Debt
1.24B
1.67B
843.23M
217.83M
565.86M
Total Liabilities
7.35B
7.83B
6.13B
5.13B
4.98B
Stockholders Equity
5.00B
4.46B
3.99B
3.58B
3.19B
Cash Flow
Free Cash Flow
923.57M
882.91M
504.68M
63.89M
847.06M
Operating Cash Flow
989.12M
1.00B
561.34M
244.95M
893.33M
Investing Cash Flow
-95.19M
70.14M
-100.29M
-350.49M
70.67M
Financing Cash Flow
-764.69M
534.19M
472.73M
-371.24M
-393.29M
HIRAYAMA HOLDINGS Co.Ltd. Technical Analysis
Technical Analysis Sentiment
Positive
Last Price1313.00
Price Trends
50DMA
1365.63
Positive
100DMA
1270.03
Positive
200DMA
1159.54
Positive
Market Momentum
MACD
58.61
Negative
RSI
84.92
Negative
STOCH
96.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7781, the sentiment is Positive. The current price of 1313 is below the 20-day moving average (MA) of 1429.50, below the 50-day MA of 1365.63, and above the 200-day MA of 1159.54, indicating a bullish trend. The MACD of 58.61 indicates Negative momentum. The RSI at 84.92 is Negative, neither overbought nor oversold. The STOCH value of 96.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7781.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 03, 2026